ERAS
NASDAQErasca, Inc.
Healthcare · Biotechnology
Price History
Learn Why It Moved
Educational concepts related to this stock
Volume Surge
Unusual trading volume indicates heightened interest — institutional activity or news-driven demand.
Biotech Catalyst
Biotech stocks are often driven by FDA approvals, trial results, and regulatory news. Learn how binary catalysts work.
Insider Activity
Check if insiders have been buying or selling. Insider buying is one of the strongest signals in small cap trading.
Dilution Risk
Check SEC filings for active shelf registrations. Dilution is the #1 risk in small cap trading.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.